Becton Dickinson and Company (BD) revised its fiscal year 2026 profit forecast downwards by 3% due to the spin-off of its biosciences & diagnostic solutions business. The company completed a $17.5bn merger with Waters, leading to an adjusted earnings per share range of $12.35 to $12.65.

The adjustment caused BD’s shares on the NYSE to drop by almost 3% to $204 per share. Despite this, CEO Tom Polen stated that Q1 FY2026 results exceeded expectations, with profits reaching $5.25bn. Medical essentials performed the strongest, while interventional and connected care also showed growth.

Polen highlighted the company’s strong first-quarter performance and completion of the Waters transaction as significant milestones for driving shareholder value. In contrast, Boston Scientific saw an 18% decrease in its stock price after reporting flat sales in key revenue segments like electrophysiology and Watchman.

Read more at Yahoo Finance: BD shares fall by 3% after lowering FY26 profit outlook